Results 21 to 30 of about 117,912 (291)

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Journal of Clinical Oncology, 2021
PURPOSE Malignant perivascular epithelioid cell tumor (PEComa) is a rare aggressive sarcoma, with no approved treatment. To our knowledge, this phase II, single-arm, registration trial is the first prospective clinical trial in this disease ...
A. Wagner, V. Ravi, R. Riedel, K. Ganjoo, B. V. Van Tine, R. Chugh, L. Cranmer, E. Gordon, J. Hornick, H. Du, B. Grigorian, A. Schmid, S. Hou, K. Harris, D. Kwiatkowski, N. Desai, M. Dickson   +16 more
semanticscholar   +1 more source

Sirolimus induced phosphaturia is not caused by inhibition of renal apical sodium phosphate cotransporters. [PDF]

PLoS ONE, 2012
The vast majority of glomerular filtrated phosphate is reabsorbed in the proximal tubule. Posttransplant phosphaturia is common and aggravated by sirolimus immunosuppression. The cause of sirolimus induced phosphaturia however remains elusive.
Maria Haller, Stefan Amatschek, Julia Wilflingseder, Alexander Kainz, Bernd Bielesz, Ivana Pavik, Andreas Serra, Nilufar Mohebbi, Jürg Biber, Carsten A Wagner, Rainer Oberbauer   +10 more
doaj   +1 more source

Efficacy of sirolimus in children with lymphatic malformations of the head and neck

European Archives of Oto-Rhino-Laryngology, 2022
Children with extensive lymphatic malformations of the head and neck often suffer from functional impairment and aesthetic deformity which significantly affect the quality of life and may be life-threatening. Treatment with sirolimus has the potential to
S. Wiegand, A. Dietz, G. Wichmann
semanticscholar   +1 more source

Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.

JAMA dermatology, 2021
Importance Sirolimus is increasingly being used to treat various vascular anomalies, although evidence of its efficacy is lacking. Objective To assess the efficacy and safety of sirolimus for children with slow-flow vascular malformations to better ...
A. Maruani, E. Tavernier, O. Boccara, J. Mazereeuw-Hautier, S. Leducq, D. Bessis, L. Guibaud, Pierre Vabres, V. Carmignac, S. Mallet, S. Barbarot, C. Chiaverini, C. Droitcourt, A. Bursztejn, C. Lengellé, J. Woillard, D. Herbreteau, A. Le Touze, A. Joly, C. Léauté-Labrèze, J. Powell, H. Bourgoin, V. Gissot, B. Giraudeau, B. Morel   +24 more
semanticscholar   +1 more source

mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double‐Blind, Placebo‐Controlled Futility Trial and 1‐Year Biomarker Longitudinal Analysis

Movement Disorders, 2022
Multiple system atrophy (MSA) is a fatal neurodegenerative disease characterized by the aggregation of α‐synuclein in glia and neurons. Sirolimus (rapamycin) is an mTOR inhibitor that promotes α‐synuclein autophagy and reduces its associated ...
J. Palma, Jose Martinez, Patricio Millar Vernetti, Thong C Ma, Miguel A Perez, J. Zhong, Yingzhi Qian, Suman Dutta, Katherine N. Maina, Ibrar Siddique, G. Bitan, B. Ades-aron, T. Shepherd, U. Kang, H. Kaufmann   +14 more
semanticscholar   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +5 more sources

The side effect profile of sirolimus and its relationship with some variables: A retrospective study of Iranian renal transplant patients

Journal of Research in Medical Sciences, 2023
Background: Sirolimus is a potent immunosuppressive in renal transplantation. However, its use is limited by some reported side effects. The objective of this study was to determine the side effect profile of sirolimus in renal transplant patients ...
Shahrzad Shahidi, Sahar Vahdat, Abdolamir Atatpour, Shirin Meshkinfar   +3 more
doaj   +1 more source

Sirolimus as a second-line treatment for Graves’ orbitopathy

Journal of Endocrinological Investigation, 2022
A beneficial effect of sirolimus in Graves’ orbitopathy (GO) was reported, suggesting a possible use in clinical practice. We conducted an observational, single-centre, no-profit, clinical study to investigate the efficacy of sirolimus as a second-line ...
G. Lanzolla, M. N. Maglionico, Simone Comi, F. Menconi, P. Piaggi, C. Posarelli, M. Figus, C. Marcocci, M. Marinò   +8 more
semanticscholar   +1 more source

High nitrogen stainless steel drug-eluting stent - Assessment of pharmacokinetics and preclinical safety in vivo

Bioactive Materials, 2020
Pharmacokinetic analyses were performed using 20 pigs for 120-days implantation, while one sirolimus-eluting stent was implanted into one of their coronary artery.
Shanshan Chen, Zhifeng Yao, Yongbiao Guan, Hui Yang, M. Babar Shahzad, Yizhe Wu, Bingchun Zhang, Li Shen, Ke Yang   +8 more
doaj   +1 more source

Safety Evaluation of Oral Sirolimus in the Treatment of Childhood Diseases: A Systematic Review

Children, 2022
Background: Sirolimus, a mammalian target of rapamycin inhibitor, has been widely used in pediatric patients, but the safety of sirolimus in pediatric patients has not been well determined.
Zixin Zhang, Yanan Li, Guangyu Zhang, Kaiying Yang, T. Qiu, Jiangyuan Zhou, Xue-jun Gong, Yi Ji   +7 more
semanticscholar   +1 more source